Bridgebio Pharma logo

Bridgebio Pharma share price today

(BBIO)

Bridgebio Pharma share price is $26.49 & ₹2,251.01 as on 21 Dec 2024, 2.30 'hrs' IST

$26.49

0.28

(1.07%)

Market is closed - opens 8 PM, 23 Dec 2024

View live Bridgebio Pharma share price in Dollar and Rupees. Guide to invest in Bridgebio Pharma from India. Also see the sentimental analysis on Indian investors investing in Bridgebio Pharma. Get details on the Indian mutual funds that are investing in Bridgebio Pharma. Get Analyst recommendations and forecasts along with all the Bridgebio Pharma's financials.

Bridgebio Pharma share price movements

  • Today's Low: $26.02
    Today's High: $26.89

    Day's Volatility :3.24%

  • 52 Weeks Low: $21.62
    52 Weeks High: $44.32

    52 Weeks Volatility :51.22%

Bridgebio Pharma Returns

PeriodBridgebio Pharma IncSector (Health Care)Index (Russel 2000)
3 Months
4.29%
-11.1%
0.0%
6 Months
15.17%
-6.0%
0.0%
1 Year
-36.91%
2.7%
0.0%
3 Years
-34.79%
0.6%
-19.7%

Bridgebio Pharma Key Statistics

in dollars & INR

Previous Close
$26.21
Open
$26.04
Today's High
$26.89
Today's Low
$26.02
Market Capitalization
$5.0B
Today's Volume
$3.7M
52 Week High
$44.32
52 Week Low
$21.62
Revenue TTM
$217.8M
EBITDA
$-509.9M
Earnings Per Share (EPS)
$-2.42
Profit Margin
-201.53%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-1789.67%

How to invest in Bridgebio Pharma from India?

It is very easy for Indian residents to invest directly in Bridgebio Pharma from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Bridgebio Pharma stock in both Indian Rupees (INR) and US Dollars (USD). Search for Bridgebio Pharma or BBIO on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Bridgebio Pharma or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Bridgebio Pharma shares which would translate to 0.032 fractional shares of Bridgebio Pharma as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Bridgebio Pharma, in just a few clicks!

Returns in Bridgebio Pharma for Indian investors in Rupees

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Bridgebio Pharma investment value today

Current value as on today

₹1,39,110

Returns

₹39,110

(+39.11%)

Returns from Bridgebio Pharma Stock

₹36,914 (false-36.91%)

Dollar Returns

₹2,196 (+2.2%)

Indian investors sentiment towards Bridgebio Pharma

226.67%

Period: Sep 22, 2024 to Dec 21, 2024. Change in 30 Days versus previous period

Investment in Bridgebio Pharma from India has grown in the last 30 days as on Dec 22, 2024. 226.67% more purchase transactions for Bridgebio Pharma in the last 30 days versus the previous period.

564%

Period: Sep 22, 2024 to Dec 21, 2024. Change in 30 Days versus previous period

Search volume for Bridgebio Pharma on INDmoney from India has grown in the last 30 days as on Dec 22, 2024. 564% more investors are searching Bridgebio Pharma in the last 30 days versus the previous period.

Global Institutional Holdings in Bridgebio Pharma

  • Kohlberg Kravis Roberts & Co LP

    13.37%

  • Viking Global Investors LP

    13.29%

  • Vanguard Group Inc

    7.51%

  • BlackRock Inc

    6.59%

  • Aisling Capital Management LP

    3.21%

  • State Street Corp

    3.16%

Analyst Recommendation on Bridgebio Pharma

Buy

    85%Buy

    15%Hold

    0%Sell

Based on 20 Wall street analysts offering stock ratings for Bridgebio Pharma(by analysts ranked 0 to 5 stars)

Based on 20 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
17
17
16
Hold
3
3
3
Sell
0
0
0

Analyst Forecast on Bridgebio Pharma

What analysts predicted

Upside of 83.31%

Current:

$26.49

Target:

$48.56

Insights on Bridgebio Pharma

  • Price Movement

    In the last 1 month, BBIO stock has moved up by 14.0%
  • Increasing Revenue

    Revenue is up for the last 2 quarters, 2.16M → 2.73M (in $), with an average increase of 20.6% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -35.21M → -162.04M (in $), with an average decrease of 114.6% per quarter
  • BBIO vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 35.5% return, outperforming this stock by 67.2%
  • BBIO vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 23.0% return, outperforming this stock by 60.5%
  • Price to Sales

    ForBBIO every $1 of sales, investors are willing to pay $22.2, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.9 for every $1 of sales.

Bridgebio Pharma Technicals Summary

Sell

Neutral

Buy

Bridgebio Pharma is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Bridgebio Pharma Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Bridgebio Pharma Inc
13.11%
15.17%
-36.91%
-34.79%
-41.78%
Regeneron Pharmaceuticals, Inc.
-5.73%
-34.03%
-17.38%
12.23%
86.41%
Biontech Se
4.48%
30.56%
7.97%
-55.71%
237.85%
Alnylam Pharmaceuticals, Inc.
-0.55%
10.11%
28.37%
26.29%
108.55%
Vertex Pharmaceuticals Incorporated
-11.79%
-16.36%
-2.55%
77.79%
80.12%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Bridgebio Pharma Inc
NA
NA
NA
-2.58
-17.9
-0.49
NA
-6.51
Regeneron Pharmaceuticals, Inc.
17.51
17.51
1.06
45.07
0.17
0.07
NA
272.04
Biontech Se
160.8
NA
0.04
-3.11
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.19
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
32.84
NA
1.17
0.55
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Bridgebio Pharma Inc
Buy
$5.0B
-41.78%
NA
-201.53%
Regeneron Pharmaceuticals, Inc.
Buy
$77.8B
86.41%
17.51
33.61%
Biontech Se
Buy
$26.7B
237.85%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Buy
$30.8B
108.55%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Buy
$102.1B
80.12%
32.84
-4.51%

Bridgebio Pharma Dividend announcements

  • Bridgebio Pharma Earnings

    Bridgebio Pharma’s price-to-earnings ratio stands at None

    Read More

About Bridgebio Pharma

we focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting r&d with expert capabilities and placing them in a value maximizing corporate structure.
Organization
Bridgebio Pharma
Employees
550
CEO
Dr. Neil Kumar Ph.D.
Industry
Health Technology

Management People of Bridgebio Pharma

NameTitle
Dr. Neil Kumar Ph.D.
Co-Founder, CEO & Director
Dr. Charles J. Homcy M.D.
Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director
Dr. Frank P. McCormick Ph.D.
Co-Founder, Chairman of Oncology & Director
Dr. Brian C. Stephenson C.F.A., Ph.D.
CFO & Secretary
Dr. Richard H. Scheller Ph.D.
Chairman of Research & Development
Dr. Thomas Trimarchi Ph.D.
President & COO
Dr. Uma Sinha Ph.D.
Chief Scientific Officer
Grace Rauh
Vice President of Communications
Mr. Eli M. Wallace Ph.D.
Chief Scientific Officer of Oncology
Dr. Eric Michael David J.D., M.D., Ph.D.
Chief Executive Officer of Gene Therapy

Important FAQs about investing in Bridgebio Pharma from India :

What is Bridgebio Pharma share price today?

Bridgebio Pharma share price today stands at $26.49, Open: $26.04 ; Previous Close: $26.21 ; High: $26.89 ; Low: $26.02 ; 52 Week High: $44.32 ; 52 Week Low: $21.62. The stock opens at $26.04, after a previous close of $26.21. The stock reached a daily high of $26.89 and a low of $26.02, with a 52-week high of $44.32 and a 52-week low of $21.62.

Can Indians buy Bridgebio Pharma shares?

Yes, Indians can invest in the Bridgebio Pharma (BBIO) from India.

With INDmoney, you can buy Bridgebio Pharma at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Bridgebio Pharma at zero transaction cost.

How can I buy Bridgebio Pharma shares from India?

It is very easy to buy Bridgebio Pharma from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Bridgebio Pharma be purchased?

Yes, you can buy fractional shares of Bridgebio Pharma with INDmoney app.

What are the documents required to start investing in Bridgebio Pharma stocks?

To start investing in Bridgebio Pharma, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Bridgebio Pharma

Today’s highest price of Bridgebio Pharma (BBIO) is $26.89.

Today’s lowest price of Bridgebio Pharma (BBIO) is $26.02.

What is today's market capitalisation of Bridgebio Pharma

Today's market capitalisation of Bridgebio Pharma BBIO is 5.0B

What is the 52 Week High and Low Range of Bridgebio Pharma

  • 52 Week High

    $44.32

  • 52 Week Low

    $21.62

What are the historical returns of Bridgebio Pharma?

  • 1 Month Returns

    13.11%

  • 3 Months Returns

    15.17%

  • 1 Year Returns

    -36.91%

  • 5 Years Returns

    -41.78%

Who is the Chief Executive Officer (CEO) of Bridgebio Pharma

Dr. Neil Kumar Ph.D. is the current Chief Executive Officer (CEO) of Bridgebio Pharma.